Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis

Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07592585

Enrollment

360

Registered

2026-05-18

Start date

2026-05-12

Completion date

2028-05-30

Last updated

2026-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Brief summary

A multicenter, randomized, double-blind, vehicle controlled phase III clinical study to evaluate the efficacy and safety of VC005 in adults and adolescents with mild to moderate atopic dermatitis

Interventions

DRUGVC005

VC005 Placebo group with Local topical application

DRUGVC005 Placebo

VC005 Placebo group with Local topical application

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Subjects fully understand this study, are able to follow the relevant procedures of the trial, voluntarily participate in the clinical trial, and sign the informed consent form (ICF); 2. The age requirement for signing the ICF is 12 years old or above, with no gender restrictions; 3. During screening, the diagnosis of atopic dermatitis should be met according to the Hanifin-Rajka criteria.

Exclusion criteria

1. Patients whose AD course is judged by the investigator as unstable(spontaneous improvement or rapid worsening) within 2 weeks prior to baseline; 2. At screening and baseline, lesions are localized only to the hands or feet, with no prior history of involvement of other typical areas (such as the face or flexural areas); 3. Skin damage or abnormalities that may affect the evaluation of the investigational drug administration site (e.g., pigmentation, extensive scarring, tattoos, etc., at the affected area); 4. At screening and baseline, presence of skin diseases that may affect the evaluation of the administration site, including but not limited to: psoriasis, acne, skin cancer, generalized erythroderma, Netherton syndrome, etc.

Design outcomes

Primary

Measure	Time frame
Proportion of subjects achieving an Investigator's Global Assessment (IGA) response (defined as an IGA score of 0 or 1 with a reduction of ≥2 points from baseline)	Week 8

Countries

China

Contacts

CONTACTxiaojuan lai

lai_xiaojuan@vcarepharmatech.com+8615358160458

PRINCIPAL_INVESTIGATORqianjin Lu

Chinese Academy of Medical Sciences Hospital for Skin Disease

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 8, 2026